Strathclyde University’s Department Biomedical Engineering has signed an agreement with HCi VioCare Technologies which will give the company access to a range of technologies related to diabetes and amputations.

The department is a research institute for bioengineering, prosthetics and orthotics. HCi VioCare will gain access to the department’s lab space and machinery to advance research. Specifically, the company will develop technologies around prevention and management of the diabetic foot, as well as amputations and complications related to mobility constraints. A first prototype, a system for monitoring of the diabetic foot condition, is currently being tested. HCi VioCare will license the technology to a third-party.

The company is a wholly owned subsidiary of US-based HCi VioCare, which is currently setting up rehabilitation clinics across Europe. The subsidiary is responsible for research and development of technologies.

The collaboration was enabled by the company’s chief technology officer, Christos Kapatos, who received his doctorate from Strathclyde.

Financial details of the agreement have not been announced.